2023
DOI: 10.1101/2023.04.17.537181
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Structure-function Analyses Reveal Key Molecular Determinants of HIV-1 CRF01_AE Resistance to the Entry Inhibitor Temsavir

Abstract: The HIV-1 entry inhibitor temsavir prevents CD4 from interacting with the envelope glycoprotein (Env) and blocks its conformational changes. To do this temsavir relies on the presence of a residue with small side chain at position 375 in Env and is unable to neutralize viral strains like CRF01_AE carrying His375. Here we investigate the mechanism of temsavir-resistance and show that residue 375 is not the sole determinant of resistance. At least six additional residues within the gp120 inner domain layers, inc… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 66 publications
1
1
0
Order By: Relevance
“…Accordingly, a cleavage-deficient Env was resistant to temsavir, as highlighted by an absence of a decrease in recognition by bNAbs, whereas recognition by the CD4-Ig ligand was decreased, likely due to competition with the small molecule. This was consistent with recent structural studies revealing that temsavir engages gp120 in a pocket under the β20-β21 loop, sequestering three key CD4 contact residues, N425, M426, and W427 [15,16]. Altogether, these results suggest that temsavir mostly modifies Env conformation by altering its cleavage.…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…Accordingly, a cleavage-deficient Env was resistant to temsavir, as highlighted by an absence of a decrease in recognition by bNAbs, whereas recognition by the CD4-Ig ligand was decreased, likely due to competition with the small molecule. This was consistent with recent structural studies revealing that temsavir engages gp120 in a pocket under the β20-β21 loop, sequestering three key CD4 contact residues, N425, M426, and W427 [15,16]. Altogether, these results suggest that temsavir mostly modifies Env conformation by altering its cleavage.…”
Section: Discussionsupporting
confidence: 92%
“…Among them, temsavir (BMS-626529 and GSK2616713), a small molecule entry inhibitor administrated as a prodrug for fostemsavir (BMS-663068, GSK3684934, and RUKOBIA), was recently approved for the treatment of patients who have limited therapeutic options [ 13 , 14 ]. Temsavir is known to bind a conserved pocket in gp120 under its β20–β21 loop, thereby preventing CD4 interaction [ 15 , 16 ]. This molecule also stabilizes the “closed” State 1 Env conformation, which is preferentially recognized by bNAbs [ 5 , 7 ].…”
Section: Introductionmentioning
confidence: 99%